Literature DB >> 35544595

Acute inflammatory response via neutrophil activation protects against the development of chronic pain.

Marc Parisien1, Lucas V Lima2, Concetta Dagostino3, Nehme El-Hachem1, Gillian L Drury1, Audrey V Grant1, Jonathan Huising4, Vivek Verma1, Carolina B Meloto1, Jaqueline R Silva5, Gabrielle G S Dutra2, Teodora Markova2, Hong Dang6, Philippe A Tessier7, Gary D Slade8, Andrea G Nackley9, Nader Ghasemlou5, Jeffrey S Mogil2, Massimo Allegri10,11, Luda Diatchenko1.   

Abstract

The transition from acute to chronic pain is critically important but not well understood. Here, we investigated the pathophysiological mechanisms underlying the transition from acute to chronic low back pain (LBP) and performed transcriptome-wide analysis in peripheral immune cells of 98 participants with acute LBP, followed for 3 months. Transcriptomic changes were compared between patients whose LBP was resolved at 3 months with those whose LBP persisted. We found thousands of dynamic transcriptional changes over 3 months in LBP participants with resolved pain but none in those with persistent pain. Transient neutrophil-driven up-regulation of inflammatory responses was protective against the transition to chronic pain. In mouse pain assays, early treatment with a steroid or nonsteroidal anti-inflammatory drug (NSAID) also led to prolonged pain despite being analgesic in the short term; such a prolongation was not observed with other analgesics. Depletion of neutrophils delayed resolution of pain in mice, whereas peripheral injection of neutrophils themselves, or S100A8/A9 proteins normally released by neutrophils, prevented the development of long-lasting pain induced by an anti-inflammatory drug. Analysis of pain trajectories of human subjects reporting acute back pain in the UK Biobank identified elevated risk of pain persistence for subjects taking NSAIDs. Thus, despite analgesic efficacy at early time points, the management of acute inflammation may be counterproductive for long-term outcomes of LBP sufferers.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35544595     DOI: 10.1126/scitranslmed.abj9954

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  7 in total

1.  Neutrophil-Derived COX-2 has a Key Role during Inflammatory Hyperalgesia.

Authors:  Nathalia Santos Carvalho; Julia Borges Paes Lemes; Marco Pagliusi; Ana Carolina Dos Santos Machado; Kauê Franco Malange; Laís Passariello Pral; José Luís Fachi; Catarine Massucato Nishijima; Gilson Gonçalves Dos Santos; Claudia Herrera Tambeli; Cesar Renato Sartori; Marco Aurélio Ramirez Vinolo; Carlos Amilcar Parada
Journal:  Inflammation       Date:  2022-07-15       Impact factor: 4.657

2.  Chronic Supraspinatus Tendonitis Pain: An Integrative Approach for Treatment with Cross-Fiber Massage, Electroacupuncture, Far-Infrared Heat, and Photobiomodulation.

Authors:  Steve Liu
Journal:  Med Acupunct       Date:  2022-08-17

3.  Anti-inflammatory drugs could cause chronic pain.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2022-07       Impact factor: 44.711

Review 4.  Potential Neuroimmune Interaction in Chronic Pain: A Review on Immune Cells in Peripheral and Central Sensitization.

Authors:  Jia-Xuan Yang; Hong-Fei Wang; Ji-Zhun Chen; Han-Yu Li; Ji-Chen Hu; An-An Yu; Jun-Jun Wen; Si-Jia Chen; Wei-Dong Lai; Song Wang; Yan Jin; Jie Yu
Journal:  Front Pain Res (Lausanne)       Date:  2022-07-04

Review 5.  Axon Guidance Molecules and Pain.

Authors:  Elisa Damo; Manuela Simonetti
Journal:  Cells       Date:  2022-10-06       Impact factor: 7.666

6.  Significance of Immune-Related Genes in the Diagnosis and Classification of Intervertebral Disc Degeneration.

Authors:  Bo Wu; Xinzhou Huang; Mu Zhang; Wei Chu
Journal:  J Immunol Res       Date:  2022-08-30       Impact factor: 4.493

7.  Bugs improve nerve regeneration: fasting-induced, microbiome-derived metabolite enhances peripheral nerve regeneration.

Authors:  Zerina Kurtovic; Camilla I Svensson; Emerson Krock
Journal:  Signal Transduct Target Ther       Date:  2022-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.